SLE - A disease of clearance deficiency?

Rheumatology

Volumn 44, Issue 9, 2005, Pages 1101-1107

  Munoz, L E ^a   Gaipl, U S ^a   Franz, S ^a   Sheriff, A ^a   Voll, R E ^b   Kalden, J R ^a   Herrmann, Martin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apoptosis; Autoimmunity; Clearance; Necrosis; Phagocytosis; SLE

Indexed keywords

ABC TRANSPORTER A1; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1 RECEPTOR; C REACTIVE PROTEIN; CARBOHYDRATE BINDING PROTEIN; CD14 ANTIGEN; CD36 ANTIGEN; CELL SURFACE RECEPTOR; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DEOXYRIBONUCLEASE I; GAMMA INTERFERON; LECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PENTRAXIN; PHOSPHATIDYLSERINE RECEPTOR; RECEPTOR PROTEIN; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SERUM AMYLOID P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANTIBODY RESPONSE; APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; MACROPHAGE FUNCTION; MOLECULAR RECOGNITION; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

APOPTOSIS; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHAGOCYTOSIS;

EID: 24144501267     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh693     Document Type: Conference Paper

References (86)

1. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227-324.
2. Herrmann M, Voll RE, Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000;21:424-6.
3. Kuenkele S, Beyer TD, Voll RE, Kalden JR, Herrmann M. Impaired clearance of apoptotic cells in systemic lupus erythematosus: Challenge of T and B cell tolerance. Curr Rheumatol Rep 2003;5:175-7.
4. Pisetsky DS. The role of bacterial DNA in autoantibody induction. Curr Top Microbiol Immunol 2000;247:143-55.
5. Steinman CR. Circulating DNA in systemic lupus erythematosus. Isolation and characterization. J Clin Invest 1984;73:832-41.
6. Rumore PM, Steinman CR. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990;86:69-74.
7. Burlingame RW, Rubin RL. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Methods 1990;134:187-99.
8. Amoura Z, Chabre H, Koutouzov S et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994;37:1684-8.
9. Radic MZ, Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994;12:487-520.
10. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992;22:1719-28.
11. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999;42:833-43.
12. Voll RE, Roth EA, Girkontaite I et al. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997;40:2162-71.
13. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995;95:531-41.
14. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146:3-15.
15. Skulachev VP. Programmed death phenomena: From organelle to organism. Ann N Y Acad Sci 2002;959:214-37.
16. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-30.
17. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407:784-8.
18. Sheriff A, Gaipl US, Voll RE, Kalden JR, Herrmann M. Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am 2004;30:505-27, viii-ix.
19. Ren Y, Savill J. Apoptosis: The importance of being eaten. Cell Death Differ 1998;5:563-8.
20. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994;372:100-3.
21. Janeway CA. Immunobiology. The immune system in health and disease. New York: Current Biology Publications, 1999:339-58, 433-4.
22. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997;61:375-80.
23. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1
24. Fadok VA, Bratton DL, Guthrie L, Henson PM. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: Role of proteases. J Immunol 2001;166:6847-54.
25. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000;192:359-66.
26. Licht R, Dicker JW, Jacobs CW, Tax WJ, Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 2004;22:139-45.
27. Herrmann M, Voll RE, Zeller OM, Hagenhofer M, Penner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
28. Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
29. Revere P, Sabbadini MG, Fazzini F et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000;43:1663-72.
30. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418: 191-5.
31. Rovere-Querini P, Capobianco A, Scaffidi P et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825-30.
32. Brouckaert G, Kalai M, Krysko DV et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine-dependent and does not induce inflammatory cytokine production. Mol Biol Cell 2003;10:10.
33. Savill J, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990; 343:170-3.
34. Cheng HM. Apoptotic antigens, B2-glycoprotein I, and antiphospholipid autoantibodies. Blood 1996;88:4396.
35. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992;90: 1513-22.
36. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 1995;92:9580-4.
37. Platt N, da Silva RP, Gordon S. Class A scavenger receptors and the phagocytosis of apoptotic cells. Biochem Soc Trans 1998;26:639-44.
38. Luciani MF, Chimini G. The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death. EMBO J 1996;15:226-35.
39. Oka K, Sawamura T, Kikuta K et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/ apoptotic cells in endothelial cells. Proc Natl Acad Sci USA 1998;95:9535-40.
40. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392:505-9.
41. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85-90.
42. Hart SP, Smith JR, Dransfield I. Phagocytosis of opsonized apoptotic cells: Roles for 'old-fashioned' receptors for antibody and complement. Clin Exp Immunol 2004;135:181-5.
43. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001;276:1071-7.
44. Appelt U, Sheriff A, Gaipl US, Kalden JR, Voll RE, Herrmann M. Viable, apoptotic and necrotic monocytes expose phosphatidylserine: Cooperative binding of the ligand Annexin V to dying but not viable cells and implications for PS-dependent clearance. Cell Death Differ 2004;12:12.
45. Marguet D, Luciani MF, Moynault A, Williamson P, Chimini G. Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey. Nat Cell Biol 1999; 1:454-6.
46. Krahling S, Callahan MK, Williamson P, Schlegel RA. Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages. Cell Death Differ 1999; 6:183-9.
47. Callahan MK, Williamson P, Schlegel RA. Surface expression of phosphatidylserine on macrophages is required for phagocytosis of apoptotic thymocytes. Cell Death Differ 2000;7:645-53.
48. Bondanza A, Zimmermann VS, Rovere-Querini P et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 2004;200:1157-65.
49. Gaipl US, Beyer TD, Heyder P et al. Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum 2004;50:640-9.
50. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 1997;18:111-5.
51. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001;38:189-97.
52. Pereira Da Silva JA, Elkon KB, Hughes GR, Dyck RF, Pepys MB. C-reactive protein levels in systemic lupus erythematosus: A classification criterion? Arthritis Rheum 1980;23:770-1.
53. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005; 52:642-50.
54. Ogden CA, Elkon KB. Single-dose therapy for lupus nephritis: C-reactive protein, nature's own dual scavenger and immunosuppressant. Arthritis Rheum 2005;52:378-81.
55. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978;32:119-24.
56. Familian A, Zwart B, Huisman HG et al. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 2001;167:647-54.
57. Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum 2003;48:248-54.
58. Bharadwaj D, Mold C, Markham E, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol 2001;166:6735-41.
59. Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5:694-7.
60. Gaipl US, Brunner J, Beyer TD, Voll RE, Kalden JR, Herrmann M. Disposal of dying cells: A balancing act between infection and autoimmunity. Arthritis Rheum 2003;48:6-11.
61. Revere P, Peri G, Fazzini F et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000;96:4300-6.
62. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998;188:2313-20.
63. Gaipl US, Kuenkele S, Voll RE et al. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 2001;8:327-34.
64. Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 2004;35:252-60.
65. Berkel AI, Petry F, Sanal O et al. Development of systemic lupus erythematosus in a patient with selective complete C1q deficiency. Eur J Pediatr 1997;156:113-5.
66. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-9.
67. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Morey T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000;25:177-81.
68. van de Wetering JK, van Golde LM, Batenburg JJ. Collectins: Players of the innate immune system. Eur J Biochem 2004;271: 1229-49.
69. Ogden CA, deCathelineau A, Hoffmann PR et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001;194:781-95.
70. Schagat TL, Wofford JA, Wright JR. Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol 2001;166:2727-33.
71. Franz S, Gaipl U, Sheriff A, Voll R, Kalden JR, Herrmann M. The role of carbohydrates in the clearance proceess of apoptotic cells. Immunobiology 2004;209:449.
72. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000;97:1184-9.
73. Svensson B. Monocyte in vitro function in systemic lupus erythematosus (SLE). I. A clinical and immunological study. Scand J Rheumatol Suppl 1980;31:29-41.
74. Hurst NP, Nuki G, Wallington T. Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1984; 55:303-12.
75. Salmon JE, Kimberly RP, Gibofsky A, Fotino M. Defective mononuclear phagocyte function in systemic lupus erythematosus: Dissociation of Fc receptor-ligand binding and internalization. J Immunol 1984;133:2525-31.
76. Landry M. Phagocyte function and cell-mediated immunity in systemic lupus erythematosus. Arch Dermatol 1977;113:147-54.
77. Gresham HD, Ray CJ, O'Sullivan FX et al. Defective neutrophil function in the autoimmune mouse strain MRL/lpr. Potential role of transforming growth factor-beta. J Immunol 1991;146:3911-21.
78. Franz S, Gaipl U, Appelt U et al. The role of a defective clearance in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2004;6:S34.
79. Theocharis S, Sfikakis PP, Lipnick RN, Klipple GL, Steinberg AD, Tsokos GC. Characterization of in vivo mutated T cell clones from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1995;74:135-42.
80. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143: 103-12.
81. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med 1995;181:1557-61.
82. Casiano CA, Ochs RL, Tan EM. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ 1998;5:183-90.
83. Deng H, Apple R, Clare-Salzler M et al. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. J Exp Med 1993;178:1675-80.
84. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: Complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997;158:4525-8.
85. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998;16:545-68.
86. Camacho SA, Kosco-Vilbois MH, Berek C. The dynamic structure of the germinal center. Immunol Today 1998;19:511-4.